NuProbe
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2575 W Bellfort Ave Ste 200, Houston, Te...Phone Number
(857) 285-2127Website
www.nuprobe.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About NuProbe
NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China, and Suzhou, China. NuProbe's vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes. NuProbe's products and services are for Research Use Only and are not intended for In Vitro Diagnostic use.Explore more
NuProbe Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NuProbe your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if NuProbe has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on NuProbe recently announced quarterly report
Click to see if NuProbe had a recent Job posting/layoffs
Check out if NuProbe is spiking on competitors!
Product Launch: Get notified when NuProbe launches new products
Funding: Get notified immidiatlly once NuProbe has new funding data
Congratulate Masked Content for being promoted to Masked Content at NuProbe
NuProbe, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined NuProbe as Masked Content
Find 2 more new buyers
Compare Similar Companies to NuProbe
Compare insights from companies similar to NuProbe, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NuProbe is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NuProbe is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NuProbe.
NuProbe financials insights
Gather financial insights about NuProbe, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$11M
2021
Unspecified
$42M
2022
Unspecified
$5.3M
NuProbe Tech Stack
A closer look at the technologies used by NuProbe
Most Recent Scoops
Funding
Open Position
NuProbe is currently seeking a Director, Electrical Engineering. (Houston, TX)
Facilities Relocation / Expansion
NuProbe is planning to move its offices in July 2022. The move will impact approximately 10 employees at their existing office located at 2575 West Bellfort Avenue, 200, Houston, TX.
Facilities Relocation/Expansion
Management Move
Executive Move
NuProbe has announced that Marcus Mazurowski has been appointed as Associate Director, Legal Affairs.
Executive Moves
Funding
NuProbe News & Media
NuProbe Closes $50M Funding
NuProbe Global, a Houston, TX- and Shanghai, China-based genomics and molecular diagnostics company, raised $50M in funding. The round was co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund, and Panlin Capital. Existing investors Sequoia Capital China, Biotrack Capital, and Yonghua Capital and new investors Pappas Capital, Haoreng Capital, and Deguan Capital also participated in the […] The post NuProbe Closes $50M Funding appeared first on FinSMEs.NuProbe Closes $50M in New Fundraising
Houston, TX, June 02, 2022 (GLOBE NEWSWIRE) -- NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M fundraising, co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund, and Panlin Capital. Existing NuProbe investors Sequoia Capital China, Biotrack Capital, and Yonghua Capital and new investors Pappas Capital, Haoreng Capital, and Deguan Capital also participated in the round. CEC Capital served as the financial advisor for this fundraising. The funds wiNuProbe QASeq Technology Enables Simultaneous Ultrasensitive Detection of CNVs and Mutations from FFPE Tissue and cfDNA
Houston, April 05, 2022 (GLOBE NEWSWIRE) -- NuProbe, a global genomics and molecular diagnostics company, announced new published data in Nature Communications describing the use of Quantitative Amplicon Sequencing (QASeq) to simultaneously detect copy number variations (CNVs) and mutations from the same sample. The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embeddeNuProbe Technology Showcases Quantitative PCR for Simultaneous Enrichment and Identification of Multiple Rare Variants below 0.1% VAF
Houston, Jan. 18, 2022 (GLOBE NEWSWIRE) -- NuProbe, a genomics and molecular diagnostics company developing ultrasensitive assays for precision oncology research, published research today demonstrating new technology to qualitatively and quantitively detect multiple low-frequency variants in one quantitative PCR (qPCR) reaction. The new allele-specific BDA technology (As-BDA) uses qPCR to detect mutations down to 0.01% variant allele fraction (VAF) within 2 hrs.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NuProbe
Sign Up For FreeTo access detailed company insights
NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China, and Suzhou, China. NuProbe's vision is to offer affordable, timely, and accurate... Read More
